Athena Athena

X
[{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Syngene International extends Long Term Research Collaboration with Bristol Myers Squibb until 2030","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Syngene International Limited","sponsor":"Vaxart","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Syngene Set For Phase-2 Trial Of Covid Oral Tablet Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Syngene International Limited

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            VXA-CoV2-1, an oral tablet COVID-19 vaccine triggers mucosal immune responses in humans, is believed to be the first defense against airborne viruses, such as coronavirus and flu.

            Lead Product(s): VXA-CoV2-1.1-S

            Therapeutic Area: Infections and Infectious Diseases Product Name: VXA-CoV2-1.1-S

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Vaxart

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY